ex vivo gene therapy
| 2 min read
ImmunoVec will use a $40.7 million grant to advance its polymeric nanoparticle platform toward a first-in-human trial for autoimmune diseases.
| 9 min read
Two ongoing Phase 1 trials will produce the first human data on these potentially revolutionary cancer drugs.
| 4 min read
The therapy lengthened telomeres and improved immune function in people with telomere biology disorder, showing promise for treating bone marrow failure safely.
| 6 min read
Experts discussed the major hurdles of AAV gene therapy, including immunogenicity, vector design, and AAV variability.
Page 1 of 1 - 4 Total Items
